Lead Sponsor

Institut de Cancérologie de Lorraine

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

No

•Patient aged 18 and over,
•With isolated high-grade vulvar intraepithelial neoplasia OR associated with invasive cancer proven histologically by biopsy
•Naive of any vulvovaginal treatment (surgery or radiotherapy)
•No metastases
•WHO \<or equal to 3
•Contraception method for women of childbearing potential
•Patient affiliated to the social security scheme
•Patient who understood, signed and dated the information note and the
•consent form,
•Patient able and willing to follow all study procedures in accordance with the protocol.

•History of hypersensitivity to the active substance methyl aminolevulinate or to any of the components of the drug (including peanut oil and refined almond oil), soybean or peanut
•Ulceration or hyperpigmented lesions of the vulva
•Patient with porphyria
•Any previous vulvovaginal treatment (surgery or radiotherapy)
•Metastatic disease
•Patient undergoing treatment for any other invasive cancer
•Pregnant, likely to be or breastfeeding patient
•Patient deprived of liberty or under guardianship (including guardianship)
•Inability to undergo medical monitoring of the trial for geographic, social or psychological reasons.
•Patient already included in another therapeutic trial with an experimental molecule,
•Associated pathology that may prevent the patient from receiving METVIXIA application and light exposure.

Related studies

NCT05463796 · Cancer Risk, Cancer Predisposition Syndrome, and more

NCT03792516 · Vulvar Dysplasia, HPV-Related Vulvar Intraepithelial Neoplasia, and more

NCT02735109 · Vulvar Mucosa Lesions, Vulvar Intraepithelial Neoplasia

NCT02875561 · Vulvar Intraepithelial Neoplasia (VIN)

NCT03180684 · Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar Dysplasia, and more

Evaluation of New Diagnostic Tool Using Fluorescence to Detect High-grade Vulvar Intraepithelial Neoplasia